Evidence map›Paper›PMID 37414508›Full record

ArticleClinical therapeutics2023

Medical Cannabis Program Sustainability in the Era of Recreational Cannabis.

Alexander M Colby, Julia A Dilley, Hailey M Pensky, Julie K Johnson

Open access · bronzeAbstract read
In one paragraph

Article in Clinical therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Evidence synthesis of medical cannabis research: current challenges and opportunities.European archives of psychiatry and clinical neuroscience · 2025
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Alexander M ColbyMassachusetts Cannabis Control Commission, Worcester, Massachusetts, USA. Electronic address: alexander.colby@cccmass.com.
Julia A DilleyProgram Design and Evaluation Services, Multnomah County/Oregon Public Health Division, Portland, Oregon, USA.
Hailey M PenskyMassachusetts Cannabis Control Commission, Worcester, Massachusetts, USA.
Julie K JohnsonMassachusetts Cannabis Control Commission, Worcester, Massachusetts, USA.
Boston Public Health Commission · US

Funding

Marijuana Legalization: Assessing the Impact of Local Regulatory PoliciesR01DA039293 · NIDA · MULTNOMAH COUNTY HEALTH DEPARTMENT · PI DILLEY, JULIA ANN · 2015 to 2024
$3.6M
NIDA NIH HHS R01 DA039293
6 · The paper itself

Abstract

purposeSince October 2022, a total of 21 states have enacted both medical-use and adult-use cannabis legalization, each with their own unique set of laws, regulations, implementation, structures, and enforcement ("policies"). Unlike adult-use programs, medical-use programs often represent a safer and affordable option for patients with diverse needs; however, current evidence suggests that medical-use program activity decreases after implementation of adult-use retail. The current study compares medical patient registration data and medical- and adult-use retail data from 3 distinct medical- and adult-use states (Colorado, Massachusetts, and Oregon) in the time after adult-use retail implementation in each state.

methodsTo investigate changes in medical cannabis programs with simultaneous adult-use legalization, correlation and linear regression analyses were used to assess outcome measures: (1) medical-use retail sales; (2) adult-use retail sales; and (3) number of registered medical patients in all fiscal quarters after adult-use retail sales were implemented in each state to September 2022.

findingsAdult-use cannabis sales increased significantly over time in all 3 states. However, both medical-use sales and number of medical patients registered in the states increased only in Massachusetts. IMPLICATIONS: Results indicate that states' preexisting medical-use programs may undergo critical changes after adult-use cannabis legalization is enacted and implemented. Key policy and program differences, such as regulatory differences in the implementation of adult-use retail sales, may have differential impacts on medical-use programs. For continued patient access, it is critical that future research assess the differences within and between states' medical-use and adult-use programs that permit sustainability of medical-use programs alongside adult-use legalization and implementation.

Indexed as

CannabisMarijuana SmokingMedical MarijuanaAdultCannabinoid Receptor AgonistsHumansLegislation, DrugProgram EvaluationCannabinoid Receptor AgonistsMedical MarijuanaCannabisCannabis policyMarijuanaMedical cannabisRecreational cannabis

Identifiers

PMID37414508
PMCPMC11221586
OpenAlexW4383100332

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.